Read by QxMD icon Read

renal cell carcinoma immunohistochemistry

Tarik Mahfoud, Rachid Tanz, Mohamed Réda Khmamouche, Mohamed Allaoui, Rhizlane Belbaraka, Mouna Khouchani, Mohamed Ichou
Synchronous primary cancers involving the pancreas and kidney are extremely rare and poorly documented. We report the first case of this association treated with chemotherapy and tyrosine kinase inhibitor. A 70-year-old woman presented with a 2-month history of epigastric pain with weight loss of 12 kg. Two weeks previously, she had presented with jaundice and pelvic pain. A computed tomography (CT) scan of the body revealed the presence of an irregular mass in the body of the pancreas, encasing the celiac trunk, with dilatation of the biliary tract...
September 2017: Case Reports in Oncology
Hongchao He, Jun Dai, Xiaojing Wang, Xiaoqiang Qian, Juping Zhao, Haofei Wang, Danfeng Xu
Renal cell carcinoma (RCC) is one of the most common malignant tumors in urogenital system with an incidence accounting for about 3% of the whole body malignant tumor. NudC domain containing 1 (NudCD1), a new member of NudC family distributed in nucleus, is found to be upregulated in multiple tumors. However, its expression and role in RCC tissue has not been elucidated. NudCD1 expression in RCC tissue was measured by western blot and immunohistochemistry (IHC). NudCD1 level was elevated by overexpression vector to investigate its regulatory role on LIS1/Dynein signaling pathway...
2018: American Journal of Translational Research
Shaojin Zhang, Juanjuan He, Zhankui Jia, Zechen Yan, Jinjian Yang
BACKGROUND: Acetyl-CoA synthetase 2 (ACSS2) is highly expressed in various cancers, whereas ACSS2 expression and function in renal cell carcinoma (RCC) are unknown. METHODS: We investigated ACSS2 expression in 198 human RCC tissues using immunohistochemistry, and analyzed its clinicopathological correlation and prognostic relevance. Overexpression and knockdown of ACSS2 were used to investigate the proliferation, migration and invasion of human RCC 786-O, 769-P, and ACHN cell lines...
March 1, 2018: Urologic Oncology
Andreas Seeber, Gerald Klinglmair, Josef Fritz, Fabian Steinkohl, Kai-Christian Zimmer, Friedrich Aigner, Wolfgang Horninger, Günther Gastl, Bettina Zelger, Andrea Brunner, Renate Pichler
Nivolumab belongs to the standard therapy in the second-line setting of metastatic renal cell carcinoma (mRCC). Although deep and long-lasting responses are seen in some patients, the majority of patients will further progress. PD-L1 as predictive biomarker is still under critical evaluation. Thus, more accurate biomarkers are clearly warranted. Here, we investigated for the first time the predictive role of IDO-1, a negative immune-regulatory molecule, on clear cell RCC tissues of 15 patients undergoing nivolumab therapy...
March 2, 2018: Cancer Science
Farahnaz Norouzinia, Fariba Abbasi, Sina Dindarian, Sedra Mohammadi, Farid Meisami, Mahdi Bagheri, Hozan Mohammadi
Objective: Renal cell carcinomas (RCCs) include about 2% of adult neoplasms and 90-95% of all renal tumors. Mostly, it is possible to distinguish RCC subtypes using hematoxylin-eosin staining. However, overlapping morphologic features cause some difficulties in making a precise diagnosis. In order to render an accurate diagnosis, additional methods such as immunohistochemical staining for c-kit have been recommended. In this study, we aimed to investigate c-kit gene expression in various subtypes of RCC...
January 2018: Turkish Journal of Urology
Jingyuan Tang, Feng Wang, Gong Cheng, Shuhui Si, Xi Sun, Jie Han, Hao Yu, Wei Zhang, Qiang Lv, Ji-Fu Wei, Haiwei Yang
BACKGROUND: Wilms' tumor 1-associating protein (WTAP) plays an important role in physiological processes and the development of tumor such as cell cycle regulation. The regulation of cell cycle is mainly dependent on cyclins and cyclin-dependent protein kinases (CDKs). Recent studies have shown that CDKs are closely related to the tumor diagnosis, progression and response to treatment. However, their specific biological roles and related mechanism in renal cell carcinoma (RCC) remain unknown...
February 27, 2018: Journal of Experimental & Clinical Cancer Research: CR
Damien Ambrosetti, Maeva Dufies, Bérengère Dadone, Matthieu Durand, Delphine Borchiellini, Jean Amiel, Jacques Pouyssegur, Nathalie Rioux-Leclercq, Gilles Pages, Fanny Burel-Vandenbos, Nathalie M Mazure
BACKGROUND: Clear-cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer. Although ccRCC is characterized by common recurrent genetic abnormalities, including inactivation of the von Hippel-Lindau (vhl) tumor suppressor gene resulting in stabilization of hypoxia-inducible factors (HIFs), the tumor aggressiveness and outcome of ccRCC is variable. New biomarkers are thus required to improve ccRCC diagnosis, prognosis and therapeutic options. This work aims to investigate the expression of HIF and proteins involved in metabolism and pH regulation...
2018: PloS One
Xiuwei Zhang, Dongwei Xue, Fengxia Hao, Lingling Xie, Jiani He, Junda Gai, Yuhui Liu, Hongtao Xu, Qingchang Li, Enhua Wang
The present study aimed to assess the expression and prognostic significance of remodeling and spacing factor 1 (RSF1; HBXAP) in renal cell carcinoma (RCC). RSF1 expression was analyzed using immunohistochemistry on tissue samples from a consecutive series of 137 patients with RCC who underwent tumor resection between November 2000 and March 2004. The associations between RSF1 expression, clinicopathological factors and patient survival were investigated. Immunohistochemistry revealed that RSF1 was highly expressed in 43...
March 2018: Oncology Letters
R-J Wang, N Wang, G Cui, Y Chen, H Zhong, J Tang
OBJECTIVE: Renal cell carcinoma (RCC) is the most common malignant tumor in the urogenital system. Its easily metastatic characteristics greatly reduce the postoperative survival rate. NudCD1, as a proto-oncogene, may be involved in the proliferation, migration, and invasion of renal cell carcinoma cell. This study intends to explore the expression of NudCD1 in renal cancer tissue and its effect on renal cell behavior. PATIENTS AND METHODS: NudCD1 expression in RCC tissue was tested Western blot...
February 2018: European Review for Medical and Pharmacological Sciences
X-W Xu, S Li, F Yin, L-L Qin
OBJECTIVE: The aim of the present study was to examine the expression of miR-205 in renal cell carcinoma (RCC) tissue and carcinoma cells; also, we aimed to determine the association of miR-205 expression with the clinicopathological features and prognosis of RCC, and to explore the mechanism of miR-205. PATIENTS AND METHODS: Carcinoma tissue and adjacent normal tissue were collected from 60 patients with RCC, and the expression of miR-205 was determined by semi-quantitative PCR, followed by correlation analysis of miR-205 with clinicopathological features and prognosis...
February 2018: European Review for Medical and Pharmacological Sciences
J X Zhou, X R He, G X Song, Z G Zou, L H Wang, R Hu, H X Li
Objective: To study the pathological features, immunophenotypes, differential diagnoses and prognostic parameters of collecting duct carcinoma of the kidney (CDC). Methods: Clinical imaging, histopathology, immunohistochemistry, and survival data of 10 patients at First Affiliated Hospital of Nanjing Medical University from January 2009 to August 2017 were retrospectively analyzed along with a review of literatures. Results: The clinical symptoms of CDC were not specific, and image examinations showed space-occupying mass lesions...
February 8, 2018: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
Jiantao Xiao, Qing Shi, Weiguo Li, Xingyu Mu, Jintao Peng, Mingzi Li, Mulin Chen, Huabing Huang, Chenji Wang, Kun Gao, Jie Fan
The α-arrestins domain-containing 1 and 3 (ARRDC1 and ARRDC3) are two members of the α-arrestins family. Yes-associated protein 1 (YAP1) is a key downstream transcription co-activator of the Hippo pathway essential for cancer initiation, progression, or metastasis in clear cell renal cell carcinoma (ccRCC). The aim of this work was to elucidate the role of the α-arrestins in ccRCC tumorigenesis by identifying molecular interacting factors and exploring potential mechanisms. In this study, we identified YAP1 as a novel ARRDC3 interacting protein in RCC cells through tandem affinity purification and mass spectrometry...
2018: American Journal of Cancer Research
Jeong Hwan Park, Minsun Jung, Kyung Chul Moon
Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell carcinoma (RCC), and it has an unfavourable prognosis compared to other RCCs. Plant homeodomain finger 2 (PHF2) and CCATT/enhancer binding protein α (C/EBPα) play a role in the epigenetic regulation of adipogenesis, and their tumour suppressive functions have been elucidated. This study aimed to assess the nuclear expression of PHF2 and C/EBPα in ccRCC and to evaluate their role in pathogenesis and prognosis. The nuclear expression of PHF2 and C/EBPα was evaluated in 344 cases of ccRCC by immunohistochemistry, and adipogenesis was assessed based on cytoplasmic features...
January 2, 2018: Oncotarget
Marie Muller, Marine Guillaud-Bataille, Julia Salleron, Catherine Genestie, Sophie Deveaux, Abdelhamid Slama, Brigitte Bressac de Paillerets, Stéphane Richard, Patrick R Benusiglio, Sophie Ferlicot
Hereditary leiomyomatosis and renal cell carcinoma syndrome is characterized by an increased risk of agressive renal cell carcinoma, often of type 2 papillary histology, and is caused by FH germline mutations. A prominent eosinophilic macronucleolus with a perinucleolar clear halo is distinctive of hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cell carcinoma according to the 2012 ISUP and 2016 WHO kidney tumor classification. From an immunohistochemistry perspective, tumors are often FH-negative and S-(2-succino)-cysteine (2SC) positive...
February 6, 2018: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
Yuan Liu, Changping Men, Yingmin Xu, Kai Zhao, Lei Luo, Dahai Dong, Qinchao Yu
BACKGROUND AND OBJECTIVE: Clusterin promotes cell proliferation, motility and invasiveness in human renal cell carcinoma (RCC) cells but the underlying molecular mechanisms of this action are largely unknown. The aim of this study was to investigate the effects of clusterin on cancer cell growth, invasion and S100A4 expression and to determine the effects of clusterin on in vitro cell proliferation and migration and in vivo tumour growth in RCC cells. METHODS: We have established stable transfectants of highly invasive Caki-1 human RCC cells with expression of clusterin shRNA targeting clusterin (Caki-1/clusterin shRNA)...
January 19, 2018: Cancer Biomarkers: Section A of Disease Markers
Masashige Nishimura, Hiroshi Wada, Hidetoshi Eguchi, Yoshifumi Iwagami, Daisaku Yamada, Tadafumi Asaoka, Takehiro Noda, Kunihito Gotoh, Shogo Kobayashi, Masaki Mori, Yuichiro Doki
Since acinar cell carcinoma(ACC)of pancreas is rare, we sometimes meet a case hard to make diagnosis before surgery. We here reported a case of ACC of pancreas with extensive intraductal growth to the main pancreatic duct and the branch of the pancreatic duct. A 43-year-old man visit a clinic with a concern of uncomfortable feeling on left side abdomen. CT/MRI examination showed a ischemic tumor, 38×25 mm, in the body-tail of the pancreas, and the tumor infiltrated to left renal capsule. ERCP showed the interruption and stenosis of the pancreatic duct at the point adjacent to tumor...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Agnieszka Sliwinska-Jewsiewicka, Anna E Kowalczyk, Bartlomiej E Krazinski, Janusz Godlewski, Przemyslaw Kwiatkowski, Jolanta Kiewisz, Jedrzej Grzegrzolka, Piotr Dziegiel, Zbigniew Kmiec
BACKGROUND/AIM: SATB2 (special AT-rich sequence-binding protein 2) is a DNA-binding protein that is involved in transcriptional regulation and chromatin remodeling. SATB2 protein has been described as a promising novel marker in several human cancers. PATIENTS AND METHODS: This study compared SATB2 expression in tumor and matched unchanged renal tissues collected from 57 patients with clear cell renal cell carcinoma (ccRCC). SATB2 mRNA levels were determined by quantitative polymerase chain reaction, while SATB2 protein expression was estimated by immunohistochemistry...
February 2018: Anticancer Research
Daniel J George, Jean-François Martini, Michael Staehler, Robert J Motzer, Ahmed Magheli, Bernard Escudier, Paola Gerletti, Sherry Li, Michelle Casey, Brigitte Laguerre, Hardev S Pandha, Allan J Pantuck, Anup Patel, Maria J Lechuga, Alain Ravaud
Purpose: Adjuvant sunitinib therapy compared with placebo prolonged disease-free survival (DFS) in patients with locoregional high-risk renal cell carcinoma (RCC) in the S-TRAC trial ( number NCT00375674). A prospectively designed exploratory analysis of tissue biomarkers was conducted to identify predictors of treatment benefit. Experimental Design: Tissue blocks were used for immunohistochemistry (IHC) staining of programmed cell death ligand 1 (PD-L1), CD4, CD8, and CD68. DFS was compared between < versus ≥ median IHC parameter using the Kaplan-Meier method...
January 26, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Guang-Hua Xu, Ning Lou, Hang-Chuan Shi, Yu-Chen Xu, Hai-Long Ruan, Wen Xiao, Lei Liu, Xiang Li, Hai-Bing Xiao, Bin Qiu, Lin Bao, Chang-Fei Yuan, Ya-Li Zhou, Wen-Jun Hu, Ke Chen, Hong-Mei Yang, Xiao-Ping Zhang
BACKGROUND: Scavenger receptor class B type I (SR-BI) has been reported to be involved in carcinogenesis of several human cancers. However, it is currently unknown whether SR-BI plays a role in clear cell renal cell carcinoma (ccRCC). Here, we aimed to evaluate a tumor promotive mechanism for SR-BI in ccRCC. METHODS: The expression of SR-BI was evaluated by real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR), Western blot and immunohistochemistry (IHC) in ccRCC tissues and cell lines...
January 22, 2018: BMC Cancer
Jue Wang, Si Wang, Yun Luan, Wenhua Zhang, Chao Sun, Guanghui Cheng, Kailin Li, Qian Xin, Zhaomin Lin, Tonggang Qi, Feng Kong
Scaffold protein neural precursor cell expressed, developmentally downregulated 9 (NEDD9) is a member of the Crk-associated substrate protein family and is known to be a biomarker in multiple cancer types. It serves a critical function in regulating cell proliferation, migration, invasion and survival. The objective of this study was to evaluate the potential effects of NEDD9 in renal cell carcinoma (RCC). The expression of NEDD9 was analyzed by immunohistochemistry, western blotting and reverse transcription-quantitative polymerase chain reaction...
December 2017: Oncology Letters
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"